The article describes the development and evaluation of PiCoVac, a purified inactivated SARS-CoV-2 vaccine candidate. The vaccine was produced using the Cell Factory system and inactivated with β-propiolactone. Preclinical studies in mice, rats, and nonhuman primates (macaques) showed that PiCoVac induced SARS-CoV-2-specific neutralizing antibodies, which neutralized 10 representative strains. Three immunizations with two different doses (3 or 6 micrograms per dose) provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without observed antibody-dependent enhancement of infection. The safety of PiCoVac was evaluated in macaques, and no adverse effects were observed. These results support the clinical development and testing of PiCoVac for human use.The article describes the development and evaluation of PiCoVac, a purified inactivated SARS-CoV-2 vaccine candidate. The vaccine was produced using the Cell Factory system and inactivated with β-propiolactone. Preclinical studies in mice, rats, and nonhuman primates (macaques) showed that PiCoVac induced SARS-CoV-2-specific neutralizing antibodies, which neutralized 10 representative strains. Three immunizations with two different doses (3 or 6 micrograms per dose) provided partial or complete protection in macaques against SARS-CoV-2 challenge, respectively, without observed antibody-dependent enhancement of infection. The safety of PiCoVac was evaluated in macaques, and no adverse effects were observed. These results support the clinical development and testing of PiCoVac for human use.